^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BMS-986416

i
Other names: BMS986416, BMS 986416, ONO-7122, BMS-986416, AVID200, AVID-200, AVID 200, AVID200 DP, TGFβ receptor ectodomain-IgG Fc fusion protein
Associations
Trials
Company:
BMS, Ono Pharma
Drug class:
TGFβ inhibitor
Associations
Trials
3d
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov)
P1, N=9, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=24 --> 9
Trial completion • Enrollment change
|
BMS-986416
3d
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies (clinicaltrials.gov)
P1, N=19, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
Trial completion • Metastases
|
BMS-986416
2ms
Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGFβ depletion. (PubMed, JCI Insight)
We hereby examined the effects of TGFβ depletion by AVID200/BMS-986416(TGFβ-TRAP), a TGFβ ligand trap, on the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) murine models with different organ-specific metastasis...Notably, the most highly expressed ligands of CCR5 shifted from the immunosuppressive CCL5 to CCL7 and CCL8, which may mediate the immune agonist activity of CCR5 following TGFβ-TRAP and anti-PD-1 combination treatment. This study suggested that TGFβ depletion modulates CAF heterogeneity and potentially reprograms CAFs and myeloid cells into anti-tumor immune agonists in PDAC, supporting the validation of such effects in human specimen.
Preclinical • Journal
|
CD4 (CD4 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • CCL8 (C-C Motif Chemokine Ligand 8)
|
BMS-986416
4ms
The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination. (PubMed, Int J Mol Sci)
To rationalize possible combinations, the efficacy in the Gata1low model of drugs currently used for these patients (the JAK1/2 inhibitor Ruxolitinib) was compared with that of drugs targeting other abnormalities, such as p27kip1 (Aplidin), TGF-β (SB431542, inhibiting ALK5 downstream to transforming growth factor beta (TGF-β) signaling and TGF-β trap AVID200), P-selectin (RB40.34), and CXCL1 (Reparixin, inhibiting the CXCL1 receptors CXCR1/2). None of the drugs reduced osteopetrosis. These results suggest that future therapies for myelofibrosis should consider combining JAK1/2 inhibitors with drugs targeting hematopoietic stem cells (p27Kip1) or the pro-inflammatory milieu (TGF-β or CXCL1).
Journal
|
JAK1 (Janus Kinase 1) • TGFB1 (Transforming Growth Factor Beta 1) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
|
Jakafi (ruxolitinib) • Aplidin (plitidepsin) • BMS-986416 • reparixin (DF 1681Y)
8ms
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors (clinicaltrials.gov)
P1, N=134, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
Opdivo (nivolumab) • BMS-986416
1year
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors (clinicaltrials.gov)
P1, N=134, Recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2023 --> Jun 2028 | Trial primary completion date: Nov 2023 --> Dec 2026
Trial completion date • Trial primary completion date • Combination therapy
|
Opdivo (nivolumab) • BMS-986416
over3years
TGFβ1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. (PubMed, JCI Insight)
To assess the in vivo effects of AVID200, Gata1low mice, a murine model of MF, were treated with AVID200 resulting in the reduction in bone marrow (BM) fibrosis and an increase in BM cellularity. AVID200 treatment also increased the frequency and numbers of murine progenitor cells as well as short and long term HSCs.Collectively, these data provide the rationale for TGFβ1 blockade with AVID200 as a therapeutic strategy for MF patients.
Journal
|
JAK2 (Janus kinase 2) • TGFB1 (Transforming Growth Factor Beta 1) • GATA1 (GATA Binding Protein 1) • CDKN1C (Cyclin Dependent Kinase Inhibitor 1C) • TGFB2 (Transforming Growth Factor Beta 2)
|
JAK2 V617F
|
BMS-986416
4years
[VIRTUAL] Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial (ASH 2020)
Clinical Trial Design: Based on these findings, a phase 1 trial of AVID200 is ongoing in INT-2/high risk MF subjects resistant or intolerant to ruxolitinib; baseline platelet count of ≥ 25 x 109/L, and grade 2/3 BMF. Furthermore, AVID200 therapy improved thrombocytopenia in MF subjects which may be due to AVID200 inhibiting the effects of TGFβ1 on normal MKpoiesis. Updated subject safety and efficacy data along with correlative data will be presented.
Clinical • P1 data
|
JAK2 (Janus kinase 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
Jakafi (ruxolitinib) • BMS-986416